title: Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses.
abstract: Melanoma is a disease with high incidence in gray horses and has limited therapeutic options in metastatic disease. Gene therapy has shown some success in animal models and human patients. A randomized double-blind, placebo-controlled study was conducted to investigate 2 treatment options using cytokine-encoding plasmid DNA in horses with metastatic melanoma to induce immunologic antitumor effects. Adult gray horses with spontaneously occurring metastatic melanoma (n=26) were included in the study. Treatment of 26 gray horses with metastatic melanoma consisted of interleukin-18-encoding plasmid DNA, interleukin-12-encoding plasmid DNA, or empty plasmid DNA (control group), injected intratumorally, respectively. Tumor response was assessed using ultrasound and caliper measurements and histologic assessment of tumor biopsies. Significant tumor regression could be shown in both the treatment groups receiving IL-18 and IL-12-encoding plasmid DNA whereas placebo-treated control patients showed tumor growth over the course of the treatment. In addition, 7 of 10 tumors from horses treated with IL-18 or IL-12 showed peritumoral and/or intratumoral inflammatory infiltrates after treatment compared with 1 of the 6 in the control group. The treatment as assessed by serial blood draws and clinical investigation, was safe and well tolerated. These data suggest that the intratumoral treatment with IL-18 and IL-12-encoding plasmid DNA has antitumor effects, which is well tolerated and thus holds promise for the treatment of patients with metastatic melanoma.
authors.affiliation: Clinic for Horses, University of Veterinary Medicine Hannover, Hannover, Germany.
authors.forename: Jessika- M V
authors.initials: J
authors.lastname: Müller
authors.forename: Karsten
authors.initials: K
authors.lastname: Feige
authors.forename: Patrizia
authors.initials: P
authors.lastname: Wunderlin
authors.forename: Andreas
authors.initials: A
authors.lastname: Hödl
authors.forename: Marina L
authors.initials: ML
authors.lastname: Meli
authors.forename: Monika
authors.initials: M
authors.lastname: Seltenhammer
authors.forename: Paula
authors.initials: P
authors.lastname: Grest
authors.forename: Lesley
authors.initials: L
authors.lastname: Nicolson
authors.forename: Claude
authors.initials: C
authors.lastname: Schelling
authors.forename: Lucie M
authors.initials: LM
authors.lastname: Heinzerling
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004247:DNA / Q000235:genetics; D004311:Double-Blind Method; D005260:Female; D015316:Genetic Therapy; D006734:Horse Diseases / Q000628:therapy*; D006736:Horses; D018664:Interleukin-12 / Q000235:genetics* / Q000276:immunology; D020382:Interleukin-18 / Q000235:genetics* / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy / Q000662:veterinary*; D009362:Neoplasm Metastasis; D010919:Placebos; D010957:Plasmids
chemical_list: D020382:Interleukin-18; D010919:Placebos; D018664:Interleukin-12; D004247:DNA